Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
29.96
-0.03 (-0.10%)
At close: Jun 27, 2025, 4:00 PM
29.72
-0.24 (-0.80%)
After-hours: Jun 27, 2025, 5:48 PM EDT
Crinetics Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for Crinetics Pharmaceuticals stock ranges from a low of $54 to a high of $97. The average analyst price target of $75 forecasts a 150.33% increase in the stock price over the next year.
Price Target: $75.00 (+150.33%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Crinetics Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 7 | 7 | 7 | 7 | 7 | 5 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 12 | 12 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $81 | Strong Buy | Reiterates | $81 | +170.36% | Jun 27, 2025 |
| Stifel | Stifel | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +100.27% | Mar 25, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Maintains $92 → $91 | Buy | Maintains | $92 → $91 | +203.74% | Feb 28, 2025 |
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Feb 4, 2025 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $55 | Hold → Strong Buy | Upgrades | $55 | +83.58% | Jan 22, 2025 |
Financial Forecast
Revenue This Year
5.22M
from 1.04M
Increased by 402.12%
Revenue Next Year
45.43M
from 5.22M
Increased by 770.88%
EPS This Year
-4.58
from -3.69
EPS Next Year
-4.72
from -4.58
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.6M | 114.2M | 341.2M | ||
| Avg | 5.2M | 45.4M | 208.4M | ||
| Low | 1.7M | 25.5M | 95.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 823.2% | 2,089.4% | 651.0% | ||
| Avg | 402.1% | 770.9% | 358.8% | ||
| Low | 60.3% | 388.4% | 111.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.28 | -3.29 | -1.63 | ||
| Avg | -4.58 | -4.72 | -3.26 | ||
| Low | -4.97 | -6.05 | -4.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.